Publication AWA
At the Public Information Bulletin of the Agency for Health Technology Assessment and Tariff System (AWA) has published reviews analyses for the evaluation of reimbursement applications:
- Agamree (vamorolone) for the treatment of patients with Duchenne muscular dystrophy (DMD)
- Poltixa (apixaban) for the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with at least one risk factor
We encourage you to read the full documents and submit comments within the prescribed period of 7 days from the date of publication.
